Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtho.2017.09.1957 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.
Cancer Lett
January 2025
Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address:
Anorexia is a major cause of cancer cachexia and is induced by growth differentiation factor-15 (GDF15), which activates the rearranged during transfection (RET) protein tyrosine kinase in the hindbrain through GDF family receptor α-like (GFRAL), raising the possibility of targeting RET for cancer cachexia treatment. RET-altered cancer patients treated with RET-selective kinase inhibitors gain weight, however, it is unclear whether this results from tumor regression that improves the overall health of patients. Thus, the potential of using a RET inhibitor to address cancer cachexia remains unknown.
View Article and Find Full Text PDFClinical efficacy of platelet-rich fibrin, injectable platelet-rich fibrin, and advanced platelet-rich fibrin in regenerative endodontics: A case series.
J Conserv Dent Endod
November 2024
Department of Conservative Dentistry and Endodontics, Inderprastha Dental College and Hospital, Ghaziabad, Uttar Pradesh, India.
Background: This series investigates the efficacy of regenerative endodontic therapy (RET) using various platelet-rich fibrin (PRF) formulations in treating apical periodontitis and necrotic pulp in immature permanent teeth.
Aim: This study aims to evaluate the effectiveness of different PRF formulations in RET.
Materials And Methods: Three cases involving patients aged 15-16 with immature teeth and necrotic pulp were treated with RET using PRF, injectable PRF, and advanced PRF.
The value of multiparametric MRI radiomics and machine learning in predicting preoperative Ki-67 expression level in breast cancer.
BMC Med Imaging
January 2025
Department of Radiology, Suzhou Ninth People's Hospital, Ludang Street 2666#, Suzhou, Jiangsu, 215200, PR China.
Objective: This study was to develop a multi-parametric MRI radiomics model to predict preoperative Ki-67 status.
Materials And Methods: A total of 120 patients with pathologically confirmed breast cancer were retrospectively enrolled and randomly divided into a training set (n = 84) and a validation set (n = 36). Radiomic features were derived from both the intratumoral and peritumoral regions, extending 5 mm from the tumor boundary, using magnetic resonance imaging (MRI).
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations.
J Med Chem
January 2025
School of Pharmacy and Food Engineering, Wuyi University, Jiangmen 529020, China.
The rearranged during transfection (RET) mutation such as the G810C mutation has significantly restricted the clinical application of selective RET inhibitors in the treatment of RET-driven cancers. This study designed and evaluated RET proteolysis targeting chimeras (PROTACs) based on selpercatinib (LOXO-292), identifying as a potent and selective RET PROTAC. effectively inhibited the proliferation of BaF3 cells with various RET mutations, showing IC values of 2.
View Article and Find Full Text PDFSelpercatinib in Chinese patients with -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial.
Ther Adv Med Oncol
January 2025
Statistical Sciences, Eli Lilly and Company, Shanghai, China.
Background: Selpercatinib is approved for the treatment of -fusion-positive non-small-cell lung cancer (NSCLC).
Objective: We present a final update on LIBRETTO-321 to enhance the understanding of long-term efficacy and safety in Chinese patients.
Design: This open-label, multicenter, phase II study included patients with advanced -altered solid tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!